Development of Escherichia coli Asparaginase II for Immunosensing: A Trade-Off between Receptor Density and Sensing Efficiency

[Image: see text] The clinical success of Escherichia colil-asparaginase II (EcAII) as a front line chemotherapeutic agent for acute lymphoblastic leukemia (ALL) is often compromised because of its silent inactivation by neutralizing antibodies. Timely detection of silent immune response can rely on...

Descripción completa

Detalles Bibliográficos
Autores principales: Charbonneau, David M., Aubé, Alexandra, Rachel, Natalie M., Guerrero, Vanessa, Delorme, Kevin, Breault-Turcot, Julien, Masson, Jean-François, Pelletier, Joelle N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044767/
https://www.ncbi.nlm.nih.gov/pubmed/30023654
http://dx.doi.org/10.1021/acsomega.7b00110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044767/
https://www.ncbi.nlm.nih.gov/pubmed/30023654
http://dx.doi.org/10.1021/acsomega.7b00110

Ejemplares similares